Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Aapro, Matti; Wijk, F. H. van; Bolis, Giorgio; Chevallier, B; Burg, M.E.L. van der; Poveda, Andrés; Oliveira, Carlos; Tumolo, Salvatore; Palumbo, Scotto di; Piccart, Martine; Franchi, Massimo Piergiuseppe; Zanaboni, Flavia; Lacave, Ángel J.; Fontanelli, Rosanna; Favalli, G.; Zola, Paolo; Guastalla, Jean‐Paul; Rosso, Raffaella; Marth, Christian; Nooij, M.; Presti, M.; Scarabelli, C; Splinter, Ted A.W.; Ploch, E; Beex, L.V.A.M.; Huinink, W. Ten Bokkel; Forni, M.; Melpignano, Mauro; Blake, Peter; Kerbrat, Pierre; Mendiola, C.; Cervantes, Andrés; Goupil, A; Harper, Peter; Madroñal, C.; Namer, M.; Scarfone, Giovanna; Stoot, J.E.G.M.; Teodorović, Ivana; Coens, Corneel; Vergote, Ignace; Vermorken, Jan B.

doi:10.1093/annonc/mdg112

Cited by 193 publications

(87 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…cisplatin plus doxorubicin with or without cyclophosphamide, cyclophosphamide plus doxorubicin, carboplatin plus pegylated liposomal doxorubicin) are slightly higher than with monotherapy (ranging from 36 to 67%), PFS durations are only 4 to 8 months. [99][100][101] GOG trial 177 and French trial revealed better response rates, PFS and OS in paclitaxel-based regimens while another GOG trial 85 failed to show better outcome in all these paramenters. 77,102,103 Systemic therapy can provide meaningful palliation for patients with advanced disease that is not amenable to local therapy.…”

Section: Treatment Of Metastatic Diseasementioning

confidence: 99%

Cancer Endometrium: An Update

Kumar¹,

Goel²

2012

Journal of South Asian Federation of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Endometrial cancer is the most common gynecological cancer in developed countries and second most common in developing countries. Its incidence is increasing in postmenopausal women. Factors related to chronic estrogen exposure are associated with a higher incidence. Abnormal uterine bleeding is the cardinal symptom. All women with suspected endometrial cancer require transvaginal ultrasonography and most will undergo endometrial biopsy; more sophisticated radiological examinations are required for preoperative staging. The general approach for treatment of endometrial cancer is hysterectomy, bilateral salpingo-oophorectomy, abdominopelvic washings, lymph node evaluation and maximal surgical cytoreduction for those with advanced disease. Postoperative adjuvant therapy [vaginal brachytherapy, external beam radiation therapy (RT), chemotherapy] may be recommended depending on the estimated risk of recurrence. Individual patient characteristics and surgical as well as pathologic staging are the main factors that are used for postsurgical risk stratification, which in turn, directs the selection of adjuvant treatment.

show abstract

Section: Treatment Of Metastatic Diseasementioning

confidence: 99%

Cancer Endometrium: An Update

Kumar¹,

Goel²

2012

Journal of South Asian Federation of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

“…These two drugs therefore came to be positioned as key drugs in chemotherapy for endometrial cancer. In the 1990s, the Gynecologic Oncology Group (GOG) in the US and the European Organization for Research and Treatment of Cancer (EORTC) conducted phase III randomized comparative studies on "doxorubicin vs. doxorubicin + cisplatin (AP therapy)" in both the GOG107 12) and EORTC55872 13) trials, respectively, and the response rates of 25% vs. 42% in the GOG107 study and 43% vs. 17% in the EORTC55872 study demonstrated the efficacy of AP therapy. Although no significant differences in OS were found in the GOG-107 study, AP therapy was shown to be superior in the EORTC55872 study.…”

Section: Chemotherapy For Advanced or Recurrent Endometrial Cancermentioning

confidence: 99%

Adjuvant Chemotherapy for Endometrial Cancer

Susumu¹,

Nomura²,

Yamagami³

et al. 2012

Cancer of the Uterine Endometrium - Advances and Controversies

View full text Add to dashboard Cite

“…Two randomized studies (Table 1) compared doxorubicin + cisplatin with doxorubicin [16,17]. Both studies found that the combination gave better response rates but no significant differences in survival.…”

Section: Chemotherapy In Advanced or Recurrent Endometrial Cancermentioning

confidence: 99%

What is the Role of Chemotherapy in Endometrial Cancer?

Högberg

2011

Curr Oncol Rep

View full text Add to dashboard Cite

Adjuvant pelvic radiotherapy has the potential to eradicate micrometastases within the irradiated field but has not resulted in survival improvements in randomized studies. This illustrates the need for systemic therapy. Chemotherapy, mainly with anthracyclines, platinum compounds, and taxanes, renders high response rates although this unfortunately translates in only modest improvements in progression-free and overall survival. Better systemic treatments need to be developed. Investigations of the molecular mechanisms of endometrial cancer have identified possible targets for therapy. In advanced endometrial cancer one study shows that chemotherapy is better than whole abdominal radiotherapy, while in the adjuvant situation the combination of chemotherapy and radiotherapy appears promising.

show abstract

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Abstract: In comparison to single agent DOX, the combination of DOX-CDDP results in higher but acceptable toxicity. The response rate produced is significantly higher, and a modest survival benefit is achieved with this combination regimen, especially in patients with a good performance status.

Cited by 193 publications

References 15 publications

Cancer Endometrium: An Update

Cancer Endometrium: An Update

Adjuvant Chemotherapy for Endometrial Cancer

What is the Role of Chemotherapy in Endometrial Cancer?

Contact Info

Product

Resources

About